As costs con­tin­ue to soar ever high­er, As­traZeneca sees new HQ stick­er price gy­rate to $1.28B

As­traZeneca may have come a long ways in chang­ing its for­tunes on the R&D side of the busi­ness, but CEO Pas­cal So­ri­ot’s 8-year-old dream of build­ing a glob­al Mec­ca for the com­pa­ny in Cam­bridge, UK con­tin­ues to be be­dev­iled by cost over­runs and an un­cer­tain dead­line.

The Times is re­port­ing that the phar­ma gi­ant now ex­pects to spend £1 bil­lion pounds — $1.28 bil­lion — to com­plete the new head­quar­ters, which the com­pa­ny blue­print­ed soon af­ter So­ri­ot’s ar­rival on the job in 2012. Ini­tial­ly, the com­pa­ny laid out a £330 mil­lion bud­get and a 2016 com­ple­tion date.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER